Company profile
UroGen Pharma Ltd.
NASDAQ: URGN · Healthcare · Biotechnology
#338 of 1,418 Healthcare companies by revenue68th-percentile growth
EA Score
55CFH 38DQ 71GM 64SS 70
v0.1 · 65/100 weight · provisional
↑ market scale, 3-yr revenue growth · ↓ Piotroski F, balance-sheet leverage
Methodology →Revenue TTM
$140.5M
Rev growth YoY (TTM)
+52.9%
Net income (FY)
-$153.5M
Employees
291
as of 2026-08-09
Market cap
$2.3B
as of 2026-08-09
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$109.8M$109.8M2025
Net income-$153.5M-$153.5M2025
Operating income-$124.9M-$124.9M2025
Total assets$200.5M$200.5M2025
Liabilities$305.9M$305.9M2025
Equity-$105.5M-$105.5M2025
Revenue trend
FY2024 – FY2025 · USD
FY24
FY24
FY23
FY24
FY24
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2025
By product
Jelmyto100%
By geography
Not disclosed.
The read
What is UroGen Pharma Ltd.’s revenue?
UroGen Pharma Ltd. booked $109.8M in FY2025 revenue, growing 21% year over year — faster than most Healthcare companies we track, at a -139.8% net margin.
Peers · Healthcare
Agenus Inc.67BImmunityBio, Inc.58CAnika Therapeutics, Inc.74BOptimizeRx Corp.72BCentury Therapeutics, Inc.48DAuxly Cannabis Group Inc.75B+Neighbors
Mercer →Key facts
CEOElizabeth Barrett
SectorHealthcare
IndustryBiotechnology
HeadquartersPrinceton, NJ
ExchangeNASDAQ: URGN
Employees291
IPO date2017-05-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.